

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/052681 A1

(43) International Publication Date

11 April 2013 (11.04.2013)

WIPO | PCT

(51) International Patent Classification:

C12N 15/55 (2006.01) A61K 31/7088 (2006.01)

(21) International Application Number:

PCT/US2012/058775

(22) International Filing Date:

4 October 2012 (04.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/544,101 6 October 2011 (06.10.2011) US

(71) Applicant: SANGAMO BIOSCIENCES, INC. [US/US];
Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(72) Inventors: HOLMES, Michael, C.; c/o Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). GREGORY, Philip, D.; c/Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). URNOV, Fyodor; c/Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(74) Agent: PASTERNAK, Dahna, S.; Pasternak Patent Law, 1900 Embarcadero Rd., Suite 211, Palo Alto, California 94303 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2013/052681 A1

(54) Title: METHODS AND COMPOSITIONS FOR REGULATING HIV INFECTION

(57) Abstract: Methods and compositions for regulating HIV infection and/or replication in which an anti-HIV transgene is integrated into the genome of a cell using a nuclelease.

METHODS AND COMPOSITIONS FOR REGULATING HIV INFECTION

CROSS-REFERENCE TO RELATED APPLICATIONS

5 [0001] The present application claims the benefit of U.S. Provisional Application Nos. filed October 6, 2011, the disclosure of which is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

10 [0002] The present disclosure is in the field of genome editing, including integration of anti-HIV molecules into the genome.

BACKGROUND

[0003] Various methods and compositions for targeted cleavage of genomic DNA have been described. Such targeted cleavage events can be used, for example, to induce targeted mutagenesis, induce targeted deletions of cellular DNA sequences, and facilitate targeted recombination at a predetermined chromosomal locus. *See*, for example, United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; and International Patent Publication WO 2007/014275, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0004] Such methods have been applied to zinc finger nuclease-mediated inactivation of the human immunodeficiency virus (HIV) receptors CCR5 and CXCR4 for the modulation of HIV infection and replication. (*See, e.g.*, U.S. Patent No. 7,951,925 and U.S. Patent Publication No. 20100291048, respectively).

[0005] However, there remains a need for additional methods and compositions that can be used to express a transgene, particularly an HIV inhibitor, to modulate HIV infection and/or replication.

30 [0006] SUMMARY

Disclosed herein are anti-HIV methods and compositions. Thus, in one aspect, described herein is a nuclease comprising a DNA binding protein and a cleavage domain or cleavage half-domain for use in cleaving the genome at one or more target sites to facilitate integration of one or more anti-HIV transgenes at the

target site(s). In certain embodiments, the DNA-binding domain comprises a zinc finger protein such that the nuclease is a zinc finger nuclease (ZFN) that binds to and cleaves in a region of interest (e.g., an HIV receptor gene such as CCR5 or CXCR4 gene and/or a safe harbor gene) in the genome of a cell. *See, e.g.*, U.S. Patent No. 5,7951,925. In other embodiments, the DNA binding domain comprises a TALE protein (Transcription activator like) that binds to a target site in a region of interest (an HIV receptor gene such as CCR5 or CXCR4 gene and/or a safe harbor gene) in a genome, wherein the TALE comprises one or more engineered TALE binding domains. In one embodiment, the TALE is a nuclease (TALEN) that cleaves a target 10 genomic region of interest, wherein the TALEN comprises one or more engineered TALE DNA binding domains and a nuclease cleavage domain or cleavage half-domain. Cleavage domains and cleavage half domains can be obtained, for example, from various restriction endonucleases and/or homing endonucleases. In one embodiment, the cleavage half-domains are derived from a Type IIS restriction 15 endonuclease (e.g., *Fok I*). In certain embodiments, the zinc finger and/or TALE DNA binding domain recognizes a target site in an HIV receptor gene, for example CCR5 or CXCR4. In other embodiments, the zinc finger and/or TALE DNA binding domain recognizes a safe-harbor gene, for example a CCR5 gene, a PPP1R12C (also known as AAV S1) gene -a *Rosa26* gene, an HPRT gene (see U.S. Patent Provisional 20 App. No. 61/556,691), or an albumin gene. *See, e.g.*, U.S. Patent No. 7,951,925 and U.S. Publication Nos. 20080159996; 201000218264 and U.S. Patent Application Nos. 13/624,193 and 13/624,217. The ZFN and/or TALEN as described herein may bind to and/or cleave the region of interest in a coding or non-coding region within or adjacent to the gene, such as, for example, a leader sequence, trailer sequence or 25 intron, or within a non-transcribed region, either upstream or downstream of the coding region.

[0007] In another aspect, described herein are compositions comprising one or more of the zinc-finger and/or TALE nucleases described herein. In certain embodiments, the composition comprises one or more zinc-finger and/or TALE nucleases in combination with a pharmaceutically acceptable excipient. In some 30 embodiments, the composition comprises ZFNs and/or TALENs. In other embodiments, the composition comprises polynucleotides encoding the ZFNs and/or TALENs. In some embodiments, the nucleic acid is said composition is mRNA, while in others, the nucleic acid is DNA.

[0008] In another aspect, described herein is a polynucleotide encoding one or more ZFNs and/or TALENs described herein. The polynucleotide may be, for example, mRNA.

[0009] In another aspect, described herein is a ZFN and/or TALEN expression 5 vector comprising a polynucleotide, encoding one or more ZFNs and/or TALENs described herein, operably linked to a promoter. In one embodiment, the expression vector is a viral vector. In one aspect, the viral vector exhibits tissue specific tropism.

[0010] In another aspect, described herein is a host cell comprising one or more ZFN and/or TALEN expression vectors. The host cell may be stably 10 transformed or transiently transfected or a combination thereof with one or more ZFN or TALEN expression vectors. In one embodiment, the host cell is a stem cell, for example a hematopoietic stem/progenitor cell (*e.g.*, CD34+). In other embodiments, the one or more ZFN and/or TALEN expression vectors express one or more ZFNs and/or TALENs in the host cell. In another embodiment, the host cell may further 15 comprise an exogenous polynucleotide donor sequence. In some embodiments, the nucleases are delivered to the host cell as purified proteins.

[0011] In another aspect, described herein is a method for inserting an anti-HIV transgene into the genome of a cell using a ZFN or TALEN (or vector encoding 20 said ZFN or TALEN) as described herein such that the anti-HIV transgene (“donor” sequence) that is inserted into the gene following targeted cleavage with the ZFN and/or TALEN. The donor sequence may be present in the ZFN or TALEN vector, present in a separate vector (*e.g.*, Ad, AAV or LV vector) or, alternatively, may be introduced into the cell using a different nucleic acid delivery mechanism. Such 25 insertion of a donor nucleotide sequence into the target locus (*e.g.*, CCR5, CXCR4, other safe-harbor gene, etc.) results in the expression of the transgene under control of the target locus’s (*e.g.* CCR5, CXCR4) genetic control elements. In other embodiments, the donor sequence includes a promoter to drive the anti-HIV gene. The promoter may be constitutive or may be regulatable (inducible). In some 30 embodiments, the donor is inserted via homology driven recombination (HDR) while in others, the donor is captured during non-homologous end joining (NHEJ) following nuclelease induced cleavage. In other embodiments, the donor is supplied in a composition. In some embodiments, the composition comprises the donor and the nucleases, while in other embodiments, the composition comprises the donor without the nucleases.

[0012] In another aspect, described herein are methods of inhibiting HIV replication and/or infection in a cell, the methods comprising integrating an anti-HIV transgene into the cell using a nuclease such that the transgene is expressed and inhibits HIV replication and/or infection in the cell. In some embodiments, the 5 composition(s) comprising the nucleases and/or the donor are used to treat the cell. The donor composition can be given together with the nuclease composition or can be given sequentially. Methods of treating or preventing HIV infection and/or replication are also provided.

10 **[0013]** In any of the methods described herein, the anti-HIV transgene may be selected from the group consisting of a sequence encoding a zinc finger transcription factor that represses an HIV polyprotein, a sequence encoding a zinc finger transcription factor that represses expression of an HIV receptor, a CCR5 ribozyme, an siRNA sequence targeted to an HIV polyprotein, a sequence encoding a 15 Trim5alpha (Trim5 α) restriction factor, a sequence encoding an APOBEC3G restriction factor, a sequence encoding a RevM10 protein, other anti-HIV genes, a suicide cassette and combinations thereof.

[0014] In some aspects, the transgene encodes an RNA molecule, for example a small interfering RNA (siRNA) or a short hairpin RNA (shRNA) that inhibits HIV 20 infection and/or replication. In other aspects, the transgene may encode a therapeutic protein of interest (e.g., a zinc finger protein transcription factor, a restriction factor, an HIV protein or HIV mutant protein (e.g., RevM10) or the like). The transgene may encode a protein such that the methods of the invention can be used for protein replacement. In other aspects, the transgene may comprise engineered sequences 25 such that the sequence (RNA or expressed protein) has characteristics which give the expressed protein or RNA novel and desirable features (increased half life, changed plasma clearance characteristics etc.).

[0015] In any of the methods and compositions described herein, the cell can be, for example, a hematopoietic stem/progenitor cell (e.g., a CD34 $^{+}$ cell), a T-cell 30 (e.g., a CD4 $^{+}$ T cell), a macrophage, a dendritic cell or an antigen-presenting cell; or a cell line such as K562 (chronic myelogenous leukemia), HEK293 (embryonic kidney), PM-1(CD4 $^{+}$ T-cell), THP-1 (monocytic leukemia), SupT1 (T cell lymphoblastic Lymphoma) or GHOST(osteosarcoma). In certain embodiments, the cell is a stem cell. Specific stem cell types that may be used with the methods and

compositions of the invention include embryonic stem cells (ESC), induced pluripotent stem cells (iPSC) and hematopoietic stem/progenitor cells (HSPCs). The iPSCs can be derived from patient samples and from normal controls wherein the patient derived iPSC can be genetically modified to obtain wild type sequence at the 5 gene of interest, or normal cells can be altered to the known disease allele at the gene of interest. Similarly, the HSPCs can be isolated from a patient. These cells are then engineered to express the transgene of interest, expanded and then reintroduced into the patient.

[0016] In any of the methods described herein, the polynucleotide encoding 10 the zinc finger nuclease(s) and/or TALEN(s) can comprise DNA, RNA or combinations thereof. In certain embodiments, the polynucleotide comprises a plasmid. In other embodiments, the polynucleotide encoding the nuclease comprises mRNA.

[0017] A kit, comprising anti-HIV transgenes, ZFNs and/or TALENs is also 15 provided. The kit may comprise nucleic acids encoding the ZFNs or TALENs, (e.g. RNA molecules or ZFN or TALEN encoding genes contained in a suitable expression vector), donor molecules, suitable host cell lines, instructions for performing the methods of the invention, and the like.

[0018] These and other aspects will be readily apparent to the skilled artisan in 20 light of disclosure as a whole.

DETAILED DESCRIPTION

[0019] Disclosed herein are genomic modifications, particularly insertion of 25 an exogenous sequence, for anti-HIV compositions and methods (*i.e.*, compositions that modulate infectivity and/or replication of HIV).

[0020] Thus, in addition to nuclease-mediated inactivation of the CCR5 or CXCR4 locus (*see, e.g.*, U.S. Patent No. 7,951,925), the present invention involves insertion of one or more transgenes to provide improved anti-HIV properties to CCR5- or CXCR4-modified cells; the ability to positively select and enrich for 30 modified cells pre- or post-engraftment; and/or to build-in an improved safety measure to allow for the negative selection of modified cells, for example using a small molecule drug. Using a multi-pronged approach to target HIV at several steps in the retrovirus lifecycle in T cells or the progeny of nuclease-modified HSPCs may overcome problems associated with the emergence of resistant virus that is often

observed after long-term or repeated exposure to a single therapeutic entity or virus that evolved from being CCR5 trophic or CXCR4 trophic to having dual tropism to both co-receptors, or changes co-receptor tropism (*e.g.* CCR5 trophic evolves to be CXCR4 trophic). Also, targeting multiple steps in the entry and post-entry pathways 5 that block the virus at the stage before integration, could provide these cells with a major selective or long-term survival advantage in the peripheral blood and tissues of the immune system where viral infection has been thought to occur in the early and later stages of the disease (*e.g.*, gut lymph nodes and thymus).

[0021] In addition, any anti-HIV transgene can be introduced into patient 10 derived cells, *e.g.* patient derived hematopoietic stem/progenitor cells (HSPCs) or other types of stems cells (embryonic, induced pluripotent, neural, or mesenchymal as a non-limiting set) for use in eventual implantation into a subject. The transgene can be introduced into any region of interest in these cells, including, but not limited to, into a CCR5 gene or other safe harbor gene, preferably in a cell in which CCR5, 15 and/or CXCR4 is inactivated. These *ex vivo* altered stem cells can be re-infused for example, into the subject pre- or post-differentiation. Additionally, the anti-HIV transgene can be introduced into patient derived T cells for use in eventual infusion into a subject. The transgene can be introduced into any region of interest in these cells, including, but not limited to, into a CCR5 gene or other safe harbor gene, 20 preferably in a cell in which CCR5, and/or CXCR4 is inactivated. These altered T cells can then be expanded *ex vivo* and the infused into a subject in need. Alternately, the transgene can be directed to the subject *in vivo* as desired through the use of viral or other delivery systems that target specific tissues.

25 **General**

[0022] Practice of the methods, as well as preparation and use of the 30 compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. *See*, for example, Sambrook *et al.* MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY,

Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, "Chromatin" (P.M. Wassarman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, "Chromatin Protocols" 5 (P.B. Becker, ed.) Humana Press, Totowa, 1999.

Definitions

[0023] The terms "nucleic acid," "polynucleotide," and "oligonucleotide" are used interchangeably and refer to a deoxyribonucleotide or ribonucleotide polymer, in linear or 10 circular conformation, and in either single- or double-stranded form. For the purposes of the present disclosure, these terms are not to be construed as limiting with respect to the length of a polymer. The terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones). In general, an analogue of a particular nucleotide has the 15 same base-pairing specificity; *i.e.*, an analogue of A will base-pair with T.

[0024] The terms "polypeptide," "peptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.

[0025] "Binding" refers to a sequence-specific, non-covalent interaction 20 between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a binding interaction need be sequence-specific (e.g., contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation 25 constant (K_d) of 10^{-6} M^{-1} or lower. "Affinity" refers to the strength of binding: increased binding affinity being correlated with a lower K_d .

[0026] A "binding protein" is a protein that is able to bind non-covalently to another molecule. A binding protein can bind to, for example, a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a 30 protein-binding protein). In the case of a protein-binding protein, it can bind to itself (to form homodimers, homotrimers, *etc.*) and/or it can bind to one or more molecules of a different protein or proteins. A binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein-binding activity.

[0027] A "zinc finger DNA binding protein" (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion. The term zinc finger

5 DNA binding protein is often abbreviated as zinc finger protein or ZFP.

[0028] A "TALE DNA binding domain" or "TALE" is a polypeptide comprising one or more TALE repeat domains/units. The repeat domains are involved in binding of the TALE to its cognate target DNA sequence. A single "repeat unit" (also referred to as a "repeat") is typically 33-35 amino acids in length and exhibits at least some sequence

10 homology with other TALE repeat sequences within a naturally occurring TALE protein.

See, e.g., U.S. Patent Publication No. 20110301073, incorporated by reference herein in its entirety.

[0029] Zinc finger and TALE binding domains can be "engineered" to bind to a predetermined nucleotide sequence, for example via engineering (altering one or 15 more amino acids) of the recognition helix region of a naturally occurring zinc finger or TALE protein. Therefore, engineered DNA binding proteins (zinc fingers or TALEs) are proteins that are non-naturally occurring. Non-limiting examples of methods for engineering DNA-binding proteins are design and selection. A designed DNA binding protein is a protein not occurring in nature whose design/composition 20 results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP and/or TALE designs and binding data. See, for example, US Patents 6,140,081; 6,453,242; and 6,534,261; see also WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and 25 WO 03/016496 and U.S. Publication No. 20110301073.

[0030] A "selected" zinc finger protein or TALE is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See *e.g.*, US 5,789,538; US 5,925,523; US 6,007,988; US 6,013,453; US 6,200,759; WO 95/19431; WO 96/06166; 30 WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970 WO 01/88197; WO 02/099084 and U.S. Publication No. 20110301073.

[0031] "Recombination" refers to a process of exchange of genetic information between two polynucleotides. For the purposes of this disclosure, "homologous recombination (HR)" refers to the specialized form of such exchange

that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a "donor" molecule to template repair of a "target" molecule (*i.e.*, the one that experienced the double-strand break), and is variously known as "non-crossover gene conversion" or "short tract gene conversion," because it leads to the transfer of genetic information from the donor to the target. Without wishing to be bound by any particular theory, such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or "synthesis-dependent strand annealing," in which the donor is used to re-synthesize genetic information that will become part of the target, and/or related processes. Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.

[0032] In the methods of the disclosure, one or more targeted nucleases as described herein create a double-stranded break in the target sequence (*e.g.*, cellular chromatin) at a predetermined site, and an anti-HIV transgene ("donor" polynucleotide), having homology to the nucleotide sequence in the region of the break, can be introduced into the cell. The presence of the double-stranded break has been shown to facilitate integration of the donor sequence. The donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin. Thus, a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in a donor polynucleotide.

25 Thus, the use of the terms "replace" or "replacement" can be understood to represent replacement of one nucleotide sequence by another, (*i.e.*, replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.

[0033] In any of the methods described herein, additional pairs of zinc-finger or TALEN proteins can be used for additional double-stranded cleavage of additional target sites within the cell.

[0034] In certain embodiments of methods for targeted recombination and/or replacement and/or alteration of a sequence in a region of interest in cellular chromatin, a chromosomal sequence is altered by homologous recombination with an

exogenous anti-HIV transgene or “donor” nucleotide sequence. Such homologous recombination is stimulated by the presence of a double-stranded break in cellular chromatin, if sequences homologous to the region of the break are present.

[0035] In any of the methods described herein, the anti-HIV transgene (also known as the “donor sequence”) can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest. Thus, in certain embodiments, portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced. In other embodiments, the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs. In certain cases, a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest. In these instances, the non-homologous sequence is generally flanked by sequences of 50-1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest. In other embodiments, the donor sequence is non-homologous to the first sequence, and is inserted into the genome by non-homologous recombination mechanisms.

[0036] The cells described herein into which the anti-HIV transgenes are integrated may also be modified by partial or complete inactivation of one or more target sequences in a cell, for example by targeted integration of the transgene that disrupts expression of one or more genes of interest. Cell lines with partially or completely inactivated genes are also provided.

[0037] Furthermore, the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences (also referred to as “transgenes” or “donors”). The exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA molecules, or any type of coding or non-coding sequence, as well as one or more control elements (e.g., promoters). In addition, the exogenous nucleic acid sequence (also referred to as a transgene) may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAs), microRNAs (miRNAs), *etc.*).

[0038] "Cleavage" refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can 5 occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In certain embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.

[0039] A "cleavage half-domain" is a polypeptide sequence which, in conjunction with a second polypeptide (either identical or different) forms a complex 10 having cleavage activity (preferably double-strand cleavage activity). The terms "first and second cleavage half-domains;" "+ and – cleavage half-domains" and "right and left cleavage half-domains" are used interchangeably to refer to pairs of cleavage half-domains that dimerize.

[0040] An "engineered cleavage half-domain" is a cleavage half-domain that 15 has been modified so as to form obligate heterodimers with another cleavage half-domain (e.g., another engineered cleavage half-domain). *See, also,* U.S. Patent Publication Nos. 2005/0064474, 20070218528, 2008/0131962 and 2011/0201055, incorporated herein by reference in their entireties.

[0041] The term "sequence" refers to a nucleotide sequence of any length, 20 which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded. The term "transgene" or "donor sequence" refers to a nucleotide sequence that is inserted into a genome. A donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 1,000 25 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.

[0042] "Chromatin" is the nucleoprotein structure comprising the cellular genome. Cellular chromatin comprises nucleic acid, primarily DNA, and protein, including histones and non-histone chromosomal proteins. The majority of 30 eukaryotic cellular chromatin exists in the form of nucleosomes, wherein a nucleosome core comprises approximately 150 base pairs of DNA associated with an octamer comprising two each of histones H2A, H2B, H3 and H4; and linker DNA (of variable length depending on the organism) extends between nucleosome cores. A molecule of histone H1 is generally associated with the linker DNA. For the purposes

of the present disclosure, the term "chromatin" is meant to encompass all types of cellular nucleoprotein, both prokaryotic and eukaryotic. Cellular chromatin includes both chromosomal and episomal chromatin.

[0043] A "chromosome," is a chromatin complex comprising all or a portion 5 of the genome of a cell. The genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell. The genome of a cell can comprise one or more chromosomes.

[0044] An "episome" is a replicating nucleic acid, nucleoprotein complex or 10 other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell. Examples of episomes include plasmids and certain viral genomes.

[0045] A "target site" or "target sequence" is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.

[0046] An "exogenous" molecule is a molecule that is not normally present in 15 a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. "Normal presence in the cell" is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell. An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally-functioning endogenous molecule.

[0047] An exogenous molecule can be, among other things, a small molecule, 25 such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules. Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can 30 be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding

proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.

[0048] An exogenous molecule can be the same type of molecule as an endogenous molecule, *e.g.*, an exogenous protein or nucleic acid. For example, an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell. Methods for the introduction of exogenous molecules into cells are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (*i.e.*, liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer. An exogenous molecule can also be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from. For example, a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster.

[0049] By contrast, an "endogenous" molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions. For example, an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally-occurring episomal nucleic acid. Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.

[0050] A "fusion" molecule is a molecule in which two or more subunit molecules are linked, preferably covalently. The subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules.

25 Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a ZFP or TALE DNA-binding domain and one or more activation domains) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described *supra*). Examples of the second type of fusion molecule include, but are not limited to, a fusion between a triplex-forming nucleic acid and a polypeptide, and a fusion between a minor groove binder and a nucleic acid.

[0051] Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is

translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.

5 [0052] A "gene," for the purposes of the present disclosure, includes a DNA region encoding a gene product (see *infra*), as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory
10 sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.

15 [0053] "Gene expression" refers to the conversion of the information, contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by
20 translation of an mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.

25 [0054] "Modulation" of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing (e.g., cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP or
TALEN as described herein. Thus, gene inactivation may be partial or complete.

30 [0055] A "region of interest" is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination. A region of interest can be present in a chromosome, an episome, an organellar genome (e.g., mitochondrial, chloroplast), or an infecting viral genome, for example. A region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either

upstream or downstream of the coding region. A region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.

[0056] "Eukaryotic" cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., T-cells).

[0057] "Secretory tissues" are those tissues in an animal that secrete products out of the individual cell into a lumen of some type which are typically derived from epithelium. Examples of secretory tissues that are localized to the gastrointestinal tract include the cells that line the gut, the pancreas, and the gallbladder. Other

10 secretory tissues include the liver, tissues associated with the eye and mucous membranes such as salivary glands, mammary glands, the prostate gland, the pituitary gland and other members of the endocrine system. Additionally, secretory tissues include individual cells of a tissue type which are capable of secretion.

[0058] The terms "operative linkage" and "operatively linked" (or "operably linked") are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. By way of illustration, a transcriptional regulatory sequence, such as a 20 promoter, is operatively linked to a coding sequence if the transcriptional regulatory sequence controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors. A transcriptional regulatory sequence is generally operatively linked in *cis* with a coding sequence, but need not be directly adjacent to it. For example, an enhancer is a 25 transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.

[0059] With respect to fusion polypeptides, the term "operatively linked" can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked. For example, with respect to 30 a fusion polypeptide in which a ZFN or TALE DNA-binding domain is fused to an activation domain, the ZFN or TALE DNA-binding domain and the activation domain are in operative linkage if, in the fusion polypeptide, the ZFN or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the activation domain is able to up-regulate gene expression. When a fusion polypeptide

in which a ZFN or TALE DNA-binding domain is fused to a cleavage domain, the ZFN or TALE DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFN or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able 5 to cleave DNA in the vicinity of the target site.

[0060] A "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid. A functional fragment can possess more, fewer, 10 or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions. Methods for determining the function of a nucleic acid (*e.g.*, coding function, ability to hybridize to another nucleic acid) are well-known in the art. Similarly, methods for determining protein function are well-known. For example, the DNA-binding function of a 15 polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See Ausubel *et al.*, *supra*. The ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, both genetic and biochemical. See, for example, 20 Fields *et al.* (1989) *Nature* **340**:245-246; U.S. Patent No. 5,585,245 and PCT WO 98/44350.

[0061] A "vector" is capable of transferring gene sequences to target cells. Typically, "vector construct," "expression vector," and "gene transfer vector," mean 25 any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression vehicles, as well as integrating vectors.

Nucleases

[0062] Described herein are compositions, particularly nucleases, which are 30 useful targeting a gene for the insertion of an anti-HIV transgene, for example, nucleases that are specific for an HIV receptor such as CCR5. In certain embodiments, the nuclease is naturally occurring. In other embodiments, the nuclease is non-naturally occurring, *i.e.*, engineered in the DNA-binding domain and/or cleavage domain. For example, the DNA-binding domain of a naturally-occurring

nuclease may be altered to bind to a selected target site (e.g., a meganuclease that has been engineered to bind to site different than the cognate binding site). In other embodiments, the nuclease comprises heterologous DNA-binding and cleavage domains (e.g., zinc finger nucleases; TAL-effector nucleases; meganuclease DNA-binding domains with heterologous cleavage domains).

A. DNA-binding domains

[0063] In certain embodiments, the nuclease is a meganuclease (homing endonuclease). Naturally-occurring meganucleases recognize 15-40 base-pair cleavage sites and are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family and the HNH family. Exemplary homing endonucleases include I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII. Their recognition sequences are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort *et al.* (1997) *Nucleic Acids Res.* **25**:3379–3388; Dujon *et al.* (1989) *Gene* **82**:115–118; Perler *et al.* (1994) *Nucleic Acids Res.* **22**, 1125–1127; Jasen (1996) *Trends Genet.* **12**:224–228; Gimble *et al.* (1996) *J. Mol. Biol.* **263**:163–180; Argast *et al.* (1998) *J. Mol. Biol.* **280**:345–353 and the New England Biolabs catalogue.

[0064] In certain embodiments, the nuclease comprises an engineered (non-naturally occurring) homing endonuclease (meganuclease). The recognition sequences of homing endonucleases and meganucleases such as I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort *et al.* (1997) *Nucleic Acids Res.* **25**:3379–3388; Dujon *et al.* (1989) *Gene* **82**:115–118; Perler *et al.* (1994) *Nucleic Acids Res.* **22**, 1125–1127; Jasen (1996) *Trends Genet.* **12**:224–228; Gimble *et al.* (1996) *J. Mol. Biol.* **263**:163–180; Argast *et al.* (1998) *J. Mol. Biol.* **280**:345–353 and the New England Biolabs catalogue. In addition, the DNA-binding specificity of homing endonucleases and meganucleases can be engineered to bind non-natural target sites. See, for example, Chevalier *et al.* (2002) *Molec. Cell* **10**:895–905; Epinat *et al.* (2003) *Nucleic Acids Res.* **31**:2952–2962; Ashworth *et al.* (2006) *Nature* **441**:656–659; Paques *et al.* (2007) *Current Gene Therapy* **7**:49–66; U.S. Patent Publication No. 20070117128. The DNA-binding domains of the homing endonucleases and meganucleases may be

altered in the context of the nuclease as a whole (*i.e.*, such that the nuclease includes the cognate cleavage domain) or may be fused to a heterologous cleavage domain.

[0065] In other embodiments, the DNA-binding domain comprises a naturally occurring or engineered (non-naturally occurring) TAL effector DNA binding

5 domain. *See, e.g.*, U.S. Patent Publication No. 20110301073, incorporated by reference in its entirety herein. The plant pathogenic bacteria of the genus *Xanthomonas* are known to cause many diseases in important crop plants.

Pathogenicity of *Xanthomonas* depends on a conserved type III secretion (T3S) system which injects more than 25 different effector proteins into the plant cell.

10 Among these injected proteins are transcription activator-like effectors (TALE) which mimic plant transcriptional activators and manipulate the plant transcriptome (see Kay *et al* (2007) *Science* 318:648-651). These proteins contain a DNA binding domain and a transcriptional activation domain. One of the most well characterized TALEs is AvrBs3 from *Xanthomonas campestris* pv. *Vesicatoria* (see Bonas *et al* (1989) *Mol Gen Genet* 218: 127-136 and WO2010079430). TALEs contain a centralized domain of tandem repeats, each repeat containing approximately 34 amino acids, which are key to the DNA binding specificity of these proteins. In addition, they contain a nuclear localization sequence and an acidic transcriptional activation domain (for a review see Schornack S, *et al* (2006) *J Plant Physiol* 163(3): 256-272). In addition, in 15 the phytopathogenic bacteria *Ralstonia solanacearum* two genes, designated brg11 and hpx17 have been found that are homologous to the AvrBs3 family of *Xanthomonas* in the *R. solanacearum* biovar 1 strain GM11000 and in the biovar 4 strain RS1000 (See Heuer *et al* (2007) *Appl and Envir Micro* 73(13): 4379-4384). These genes are 98.9% identical in nucleotide sequence to each other but differ by a 20 deletion of 1,575 bp in the repeat domain of hpx17. However, both gene products have less than 40% sequence identity with AvrBs3 family proteins of *Xanthomonas*.

[0066] Thus, in some embodiments, the DNA binding domain that binds to a target site in a target locus (*e.g.*, CCR5 or safe harbor) is an engineered domain from a TAL effector similar to those derived from the plant pathogens *Xanthomonas* (see

30 Boch *et al*, (2009) *Science* 326: 1509-1512 and Moscou and Bogdanove, (2009) *Science* 326: 1501) and *Ralstonia* (see Heuer *et al* (2007) *Applied and Environmental Microbiology* 73(13): 4379-4384); U.S. Publication No. 20110301073 and U.S. Patent Publication No. 20110145940.

[0067] In certain embodiments, the DNA binding domain comprises a zinc finger protein (e.g., a zinc finger protein that binds to a target site in an HIV receptor such as CCR5 or other safe-harbor gene). Preferably, the zinc finger protein is non-naturally occurring in that it is engineered to bind to a target site of choice. *See, for example, See, for example, Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:411-416; U.S. Patent Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U.S. Patent Publication Nos. 2005/0064474; 2007/0218528; 2005/0267061, all incorporated herein by reference in their entireties.*

[0068] An engineered zinc finger binding or TALE domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein. Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. *See, for example, co-owned U.S. Patents 6,453,242 and 6,534,261, incorporated by reference herein in their entireties.*

[0069] Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186; WO 98/53057; WO 00/27878; WO 01/88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.

[0070] In addition, as disclosed in these and other references, DNA domains (e.g., multi-fingered zinc finger proteins or TALE domains) may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. *See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The DNA binding proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein. In addition, enhancement of*

binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.

[0071] Selection of target sites; DNA-binding domains and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the art and described in detail in U.S. Patent Nos. 6,140,0815; 789,538; 6,453,242; 6,534,261; 5,925,523; 6,007,988; 6,013,453; 6,200,759; WO 95/19431; WO 96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970 WO 01/88197; WO 02/099084; WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496 and U.S. Publication No. 20110301073.

[0072] In addition, as disclosed in these and other references, DNA-binding domains (e.g., multi-fingered zinc finger proteins) may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein.

B. Cleavage Domains

[0073] Any suitable cleavage domain can be operatively linked to a DNA-binding domain to form a nuclease. For example, ZFP DNA-binding domains have been fused to nuclease domains to create ZFNs – a functional entity that is able to recognize its intended nucleic acid target through its engineered (ZFP) DNA binding domain and cause the DNA to be cut near the ZFP binding site via the nuclease activity. See, e.g., Kim *et al.* (1996) *Proc Nat'l Acad Sci USA* 93(3):1156-1160. More recently, ZFNs have been used for genome modification in a variety of organisms. See, for example, United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International Publication WO 07/014275. Likewise, TALE DNA-binding domains have been fused to nuclease domains to create TALENs. See, e.g., U.S. Publication No. 20110301073.

[0074] As noted above, the cleavage domain may be heterologous to the DNA-binding domain, for example a zinc finger DNA-binding domain and a cleavage domain from a nuclease or a TALEN DNA-binding domain and a cleavage domain,

or meganuclease DNA-binding domain and cleavage domain from a different nuclease. Heterologous cleavage domains can be obtained from any endonuclease or exonuclease. Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing 5 endonucleases. *See, for example, 2002-2003 Catalogue, New England Biolabs, Beverly, MA; and Belfort *et al.* (1997) *Nucleic Acids Res.* **25**:3379-3388. Additional enzymes which cleave DNA are known (e.g., S1 Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease; *see also* Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993).* One or more of 10 these enzymes (or functional fragments thereof) can be used as a source of cleavage domains and cleavage half-domains.

[0075] Similarly, a cleavage half-domain can be derived from any nuclease or portion thereof, as set forth above, that requires dimerization for cleavage activity. In general, two fusion proteins are required for cleavage if the fusion proteins comprise 15 cleavage half-domains. Alternatively, a single protein comprising two cleavage half-domains can be used. The two cleavage half-domains can be derived from the same endonuclease (or functional fragments thereof), or each cleavage half-domain can be derived from a different endonuclease (or functional fragments thereof). In addition, the target sites for the two fusion proteins are preferably disposed, with respect to 20 each other, such that binding of the two fusion proteins to their respective target sites places the cleavage half-domains in a spatial orientation to each other that allows the cleavage half-domains to form a functional cleavage domain, *e.g.*, by dimerizing. Thus, in certain embodiments, the near edges of the target sites are separated by 5-8 nucleotides or by 15-18 nucleotides. However any integral number of nucleotides or 25 nucleotide pairs can intervene between two target sites (*e.g.*, from 2 to 50 nucleotide pairs or more). In general, the site of cleavage lies between the target sites.

[0076] Restriction endonucleases (restriction enzymes) are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding. Certain restriction enzymes (*e.g.*, 30 Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS enzyme *Fok* I catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. *See, for example, US Patents 5,356,802; 5,436,150 and 5,487,994; as well as Li *et al.* (1992) *Proc. Natl.**

Acad. Sci. USA **89**:4275-4279; Li *et al.* (1993) *Proc. Natl. Acad. Sci. USA* **90**:2764-2768; Kim *et al.* (1994a) *Proc. Natl. Acad. Sci. USA* **91**:883-887; Kim *et al.* (1994b) *J. Biol. Chem.* **269**:31,978-31,982. Thus, in one embodiment, fusion proteins

5 comprise the cleavage domain (or cleavage half-domain) from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered.

[0077] An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is *Fok* I. This particular enzyme is active as a dimer. Bitinaite *et al.* (1998) *Proc. Natl. Acad. Sci. USA* **95**: 10,570-10,575.

10 Accordingly, for the purposes of the present disclosure, the portion of the *Fok* I enzyme used in the disclosed fusion proteins is considered a cleavage half-domain. Thus, for targeted double-stranded cleavage and/or targeted replacement of cellular sequences using zinc finger-*Fok* I fusions, two fusion proteins, each comprising a *Fok* I cleavage half-domain, can be used to reconstitute a catalytically active cleavage

15 domain. Alternatively, a single polypeptide molecule containing a DNA binding domain and two *Fok* I cleavage half-domains can also be used.

[0078] A cleavage domain or cleavage half-domain can be any portion of a protein that retains cleavage activity, or that retains the ability to multimerize (*e.g.*, dimerize) to form a functional cleavage domain.

20 [0079] Exemplary Type IIS restriction enzymes are described in International Publication WO 07/014275, incorporated herein in its entirety. Additional restriction enzymes also contain separable binding and cleavage domains, and these are contemplated by the present disclosure. *See*, for example, Roberts *et al.* (2003) *Nucleic Acids Res.* **31**:418-420.

25 [0080] In certain embodiments, the cleavage domain comprises one or more engineered cleavage half-domain (also referred to as dimerization domain mutants) that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 20050064474; 20060188987 and 20080131962, the disclosures of all of which are incorporated by reference in their entireties herein. Amino acid

30 residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537, and 538 of *Fok* I are all targets for influencing dimerization of the *Fok* I cleavage half-domains.

[0081] Exemplary engineered cleavage half-domains of *Fok* I that form obligate heterodimers include a pair in which a first cleavage half-domain includes

mutations at amino acid residues at positions 490 and 538 of *Fok I* and a second cleavage half-domain includes mutations at amino acid residues 486 and 499.

[0082] Thus, in one embodiment, a mutation at 490 replaces Glu (E) with Lys (K); the mutation at 538 replaces Iso (I) with Lys (K); the mutation at 486 replaced 5 Gln (Q) with Glu (E); and the mutation at position 499 replaces Iso (I) with Lys (K). Specifically, the engineered cleavage half-domains described herein were prepared by mutating positions 490 (E→K) and 538 (I→K) in one cleavage half-domain to produce an engineered cleavage half-domain designated “E490K:I538K” and by mutating positions 486 (Q→E) and 499 (I→L) in another cleavage half-domain to 10 produce an engineered cleavage half-domain designated “Q486E:I499L”. The engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. *See, e.g.*, U.S. Patent Publication No. 2008/0131962, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0083] In certain embodiments, the engineered cleavage half-domain 15 comprises mutations at positions 483, 486, 487, 499, 496 and 537 (numbered relative to wild-type FokI), for instance mutations that replace the wild type Gln (Q) residue at position 486 with a Glu (E) residue, the wild type Iso (I) residue at position 499 with a Leu (L) residue and the wild-type Asn (N) residue at position 496 with an Asp (D) or 20 Glu (E) residue (also referred to as a “ELD” and “ELE” domains, respectively). In other embodiments, the engineered cleavage half-domain comprises mutations at positions 490, 538 and 537 (numbered relative to wild-type FokI), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue, the wild type Iso (I) residue at position 538 with a Lys (K) residue, and the 25 wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as “KKK” and “KKR” domains, respectively). In other embodiments, the engineered cleavage half-domain comprises mutations at positions 490 and 537 (numbered relative to wild-type FokI), for instance mutations that 30 replace the wild type Glu (E) residue at position 490 with a Lys (K) residue and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as “KIK” and “KIR” domains, respectively). *See, US Patent Publication No. 20110201055.* In still further embodiments, the engineered cleavage half domains comprise mutations such that a nuclease pair is made with one H537R-

R487D-N496D (“RDD”) *FokI* half domain and one N496D-D483R-H537R (“DRR”)

FokI half domain. *See*, US Patent Publication No. 20110201055.

[0084] Engineered cleavage half-domains described herein can be prepared using any suitable method, for example, by site-directed mutagenesis of wild-type cleavage half-domains (*Fok I*) as described in U.S. Patent Publication Nos. 20050064474; 20080131962 and 20110201055.

[0085] Alternatively, nucleases may be assembled *in vivo* at the nucleic acid target site using so-called “split-enzyme” technology (*see e.g.* U.S. Patent Publication No. 20090068164). Components of such split enzymes may be expressed either on separate expression constructs, or can be linked in one open reading frame where the individual components are separated, for example, by a self-cleaving 2A peptide or IRES sequence. Components may be individual zinc finger binding domains or domains of a meganuclease nucleic acid binding domain.

[0086] Nucleases can be screened for activity prior to use, for example in a yeast-based chromosomal system as described in WO 2009/042163 and 20090068164. Nuclease expression constructs can be readily designed using methods known in the art. *See, e.g.*, United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International Publication WO 07/014275. Expression of the nuclease may be under the control of a constitutive promoter or an inducible promoter, for example the galactokinase promoter which is activated (de-repressed) in the presence of raffinose and/or galactose and repressed in presence of glucose.

Target Sites

[0087] As described in detail above, DNA domains can be engineered to bind to any sequence of choice in a locus, for example a CCR5, CXCR4 or other safe-harbor gene such as AAVS1, HPRT, *Rosa* or albumin. *See, e.g.*, U.S. Publication Nos. 20080159996 and 201000218264; U.S. Provisional Application No. 61/556,691 and U.S. Patent Application Nos. 13/624,193 and 13/624,217. An engineered DNA-binding domain can have a novel binding specificity, compared to a naturally-occurring DNA-binding domain. Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual (*e.g.*, zinc finger) amino acid sequences, in which each triplet or quadruplet

nucleotide sequence is associated with one or more amino acid sequences of DNA binding domain which bind the particular triplet or quadruplet sequence. *See*, for example, co-owned U.S. Patents 6,453,242 and 6,534,261, incorporated by reference herein in their entireties. Rational design of TAL-effector domains can also be performed. *See, e.g.*, U.S. Publication No. 20110301073.

5 [0088] Exemplary selection methods applicable to DNA-binding domains, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186; WO 98/53057; WO 00/27878; WO 01/88197 10 and GB 2,338,237.

15 [0089] Selection of target sites; nucleases and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the art and described in detail in U.S. Patent Application Publication Nos. 20050064474 and 20060188987, incorporated by reference in their entireties herein.

20 [0090] In addition, as disclosed in these and other references, DNA-binding domains (*e.g.*, multi-fingered zinc finger proteins) may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids. *See, e.g.*, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual DNA-binding domains of the protein. *See, also*, U.S. Publication No. 20110301073.

25 [0091] Non-limiting examples of suitable target cells include, for example, peripheral Blood Mononuclear Cells (PBMCs), macrophages, mesenchymal stem cells, human embryonic stem cells (hES cells), hematopoietic stem/progenitor cells (*e.g.*, CD34⁺ cells), T-cells (*e.g.*, CD4⁺ cells), dendritic cells or antigen-presenting cells; or a cell line such as K562 (chronic myelogenous leukemia), HEK293 (embryonic kidney), PM-1(CD4⁺ T-cell), THP-1 (monocytic leukemia), SupT1 (T cell lymphoblastic Lymphoma) or GHOST(osteosarcoma).

30

Donors

[0092] As noted above, insertion of an anti-HIV transgene (also called a “donor sequence” or “donor” or “exogenous sequence”), for example for expression of the anti-HIV transgene in an inactivated locus. It will be readily apparent that the

donor sequence is typically not identical to the genomic sequence where it is placed. A donor sequence can contain a non-homologous sequence flanked by two regions of homology to allow for efficient HDR at the location of interest. Additionally, donor sequences can comprise a vector molecule containing sequences that are not

5 homologous to the region of interest in cellular chromatin. A donor molecule can contain several, discontinuous regions of homology to cellular chromatin. For example, for targeted insertion of sequences not normally present in a region of interest, said sequences can be present in a donor nucleic acid molecule and flanked by regions of homology to sequence in the region of interest.

10 [0093] The donor polynucleotide can be DNA, single-stranded or double-stranded and can be introduced into a cell in linear or circular form. In addition, single-stranded or double-stranded oligonucleotides may be used for donors. *See, e.g.*, U.S. Patent Publication Nos. 20100047805; 20110281361; and 20110207221. If introduced in linear form, the ends of the donor sequence can be protected (*e.g.*, from 15 exonucleolytic degradation) by methods known to those of skill in the art. For example, one or more dideoxynucleotide residues are added to the 3' terminus of a linear molecule and/or self-complementary oligonucleotides are ligated to one or both ends. *See, for example, Chang et al. (1987) Proc. Natl. Acad. Sci. USA* **84**:4959-4963; Nehls et al. (1996) *Science* **272**:886-889. Additional methods for protecting 20 exogenous polynucleotides from degradation include, but are not limited to, addition of terminal amino group(s) and the use of modified internucleotide linkages such as, for example, phosphorothioates, phosphoramidates, and O-methyl ribose or deoxyribose residues.

25 [0094] A polynucleotide can be introduced into a cell as part of a vector molecule having additional sequences such as, for example, replication origins, promoters and genes encoding antibiotic resistance. Moreover, donor polynucleotides can be introduced as naked nucleic acid, as nucleic acid complexed with an agent such as a liposome or poloxamer, or a macromolecule such as a dendrimir (See Wijagkanalen et al (2011) *Pharm Res* 28(7) p. 1500-19), or can be delivered by 30 viruses (*e.g.*, adenovirus, helper-dependent adenovirus, AAV, herpesvirus, retrovirus, lentivirus and integrase defective lentivirus (IDLV)).

[0095] The donor can be inserted so that its expression is driven by the endogenous promoter at the integration site, for example the promoter that drives expression of the endogenous CCR5 or CXCR4 gene. However, it will be apparent

that the donor may comprise a promoter and/or enhancer, for example a constitutive promoter or an inducible or tissue specific promoter. The donor molecule may be inserted into any endogenous gene such that all, some or none of the endogenous gene is expressed. In certain embodiments, the donor transgene is integrated into an endogenous CCR5 locus such that the CCR5 gene is inactivated. *See, e.g.*, U.S. Patent No. 7,951,925. In other embodiments, the exogenous sequence is integrated into an endogenous locus other than CCR5 for example, a safe harbor gene such as a PPP1R12C (also known as AAV S1) gene, a *Rosa26* gene, an HPRT gene or an albumin gene (*see, e.g.*, U.S. Publication Nos. 20080159996 and 201000218264; U.S. Provisional No. 61/556,691; U.S. Patent Application Nos. 13/624,193 and 13/624,217) but in which the CCR5 and/or CXCR4 gene is inactivated in the cell (for example via a nuclease).

15 [0096] Furthermore, although not required for expression, exogenous sequences may also include transcriptional or translational regulatory sequences, for example, promoters, enhancers, insulators, internal ribosome entry sites, sequences encoding 2A peptides and/or polyadenylation signals.

20 [0097] Non-limiting examples of suitable anti-HIV transgenes, which may be used alone or in any combination, are described below. It will be apparent that the compositions and methods described herein can include any combination of donors integrated into any number of loci, for example, one, some or all of the transgenes may be integrated into (and inactivate) a CCR5 gene. Alternatively, one, some or all of the transgenes may be integrated into one or more endogenous genes (*e.g.*, safe harbor genes) in which an endogenous CCR5 gene is inactivated (*e.g.*, via a nuclease).

25 Small interfering RNAs (siRNAs) and shRNA

30 [0098] Small interfering RNAs (siRNAs) are potent inhibitors of gene expression and can cleave both cellular and viral transcripts that have made them an attractive tool for use in an HIV gene therapy application (Song *et al.* (2003) *J. Virol.* 77(13):7174-81; Lee *et. al* (2002) *Nat. Biotech* 20(5):500-5). Several studies using siRNAs targeting essential HIV genes (*e.g.* gag, nef, and tat) have demonstrated a block or reduction in HIV replication *in vitro* (Han *et. al* (2004) *Virology* 330(1):221-32; Lee *et. al* (2003) *J. Virol.* 77(22):11964-72; Das *et. al.* (2004) *J Virol.* 78(5):2601-5. For example, an siRNA gene targeting the sequence overlapping both the rev and tat open reading frames has been shown to be effective in reducing HIV replication

when delivered into model cell lines, PBMCs, and CD34+ cells. *See, e.g.,* Lee *et. al.* (2002) *Nat. Biotech* 20(5):500-5). Thus, in certain embodiments, the transgene comprises one or more siRNA sequence targeted to an HIV polyprotein, for example, rev, tat, gag, nef, pol, and/or env. The siRNAs may be in the sense and/or antisense 5 orientation and maybe under the control of any promoter, for example a U6 RNA polIII promoter.

[0099] However, in long-term cultures HIV has been shown to mutate and escape from the inhibitory effects of siRNA. *See, e.g.,* Das *et. al.* (2004) *J Virol.* 78(5):2601-5; Westerhout *et. al.* (2005) *Nucleic Acids Res.* 33(2):796-804. 10 Accordingly, provided herein are donors that include combinations that encode one or more siRNA molecules and one or more additional anti-HIV therapeutics. Non-limiting examples of additional anti-HIV molecules, include one or more CCR5 ribozymes, a TAR decoy, a polypeptide (*e.g.*, transcription factor, enzyme, etc.) and/or one or more short hairpin (shRNA) molecules. *See, e.g.,* Li *et al.* (2003) *Mol. 15 Therapy* 8(2):196-205. The siRNA and additional molecules (*e.g.*, shRNA) may be under the control of same or different promoters. Thus, in certain embodiments, an shRNA expression cassette (*e.g.*, U6-shRNA) is included in the donor transgene for integration into the CCR5 locus, thereby linking the disruption of CCR5 with the stable expression of inhibitors of both HIV tat and rev.

20

Engineered transcription factors

[0100] In other embodiments, the anti-HIV transgenes as described herein include sequences encoding one or more engineered (non-naturally occurring) transcription factors, for example zinc finger transcription factors, which include 25 engineered (non-naturally occurring) zinc finger domains fused to transcriptional regulatory domains such as activators or repressors (*e.g.*, KRAB, KOX, etc.). *See, e.g.,* U.S. Patent Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U.S. Patent Publication Nos. 2005/0064474; 2007/0218528; 2005/0267061, all 30 incorporated herein by reference in their entireties.

[0101] The transcription factors integrated in to the cell may be targeted to, for example, any of the HIV-encoding sequences, *e.g.*, gag, env, tat, rev, nef, vpr, vpu, vif, etc. In certain embodiments, the engineered transcription factor is targeted to the HIV-1 5'LTR, for example to sites that are highly conserved as between HIV strains,

to block viral RNA expression. *See, e.g.,* Reynolds *et al.* (2003) *Proc. Nat'l. Acad. Sci. USA* 100(4):1615-1620; Eberhardy *et. al.* (2006) *J Virol.* 80(6):2873-83.

[0102] In still further embodiments, the transgene comprises a sequence encoding an engineered transcription factor that represses an HIV receptor or co-receptor (in addition to CCR5). In certain embodiments, the HIV co-receptor targeted by the repressor is CXCR4, which leads to the simultaneous disruption of both HIV CCR5 and CXCR4 receptors. The transgene may be under the control of any endogenous or exogenous promoter (*e.g.*, an inducible or tissue-specific promoter). Thus, given the requirement for CXCR4 in stem cell homing and subsequent B-cell development, targeted integration of a CXCR4 repressor as described herein can be restricted to a cell type of choice, for example into HSPCs and/or CD4+ T-cells by selecting the appropriate control elements (*e.g.*, an RNA polII promoter, and/or CD4-specific promoter/enhancer).

15 Retroviral Restriction Factors

[0103] Another class of anti-HIV therapeutic transgenes that can be incorporated into the targeted integration approach include wild-type and/or modified variants of two human retroviral restriction factors, Trim5alpha (Trim5 α) and APOBEC3G. *See, e.g.,* Malim *et al.* (2012) *Cold Spring Harbor Perspect Med.* May; 2(5): a006940.

[0104] The restriction factor TRIM5 is thought to form a trimer and function by binding to the virus capsid soon after entry, thus, interfering with the proper uncoating of the virus and blocking infection at some point before or during reverse transcription. *See, Keckesova *et al.* (2004) Proc. Natl. Acad. Sci. USA* 101:10780–10785; Stremlau *et al.* (2004) *Nature* 427:848–853; Ylinen *et al.* (2005) *J. Virol.* 79(18):11580-7; Yap *et al.* (2004) *Proc. Natl. Acad. Sci. USA* 101:10786–10791; Li *et al.* (2006) *J. Virol.* 80(14):6738-44.

[0105] The second restriction factor, APOBEC3G, is part of a family of proteins with cytidine deaminase function. *See, e.g.,* Chiu & Greene (2008) *Annu Rev Immunol.* 26:317-53. APOBEC3G edits ssDNA, causing deamination of dC residues in the minus-strand into dU residues. In the case of HIV, this process occurs in a graded fashion with residues closer to the start of RT being more extensively edited, although up to 20% of all minus-strand dC residues can be edited. This editing can lead to either G-A hypermutations in the plus-strand that can lead to the generation of

defective provirus. *See, e.g.*, Harris *et al.*, (2003) *Cell* 113(6):803-9; Mangeat *et al.* (2003) *Nature* 424(6944):99-103; Yu *et al.* (2004) *Nat. Strut. Mol. Biol.* 11(5):435-42; Zhang *et al.* (2003) *Nature* 424(6944):94-8. Normally, HIV inactivates APOBEC3G through Vif binding which destabilizes APOBEC3G via ubiquitination, followed by 5 degradation by the proteasome (Yu *et al.* (2003) *Science* 302(5647):1056-60). However, HIV-1 is potently restricted in human cells by rhesus APOBEC3G, presumably through the inability of Vif to efficiently bind and modify APOBEC3G. This difference in activity has been mapped to a single amino acid, aspartic acid (D) to lysine (K) at wild-type position (D128K) in the rhesus protein. Mutating the 10 human gene to synthesize a D128K variant generates a human APOBEC3G which is resistant to Vif. *See, e.g.*, Xu *et al.* (2004) *Proc. Nat'l. Acad. Sci. USA* 101(15):5652-7.

[0106] Thus, in some aspects, the transgene (*e.g.*, integrated into the CCR5 locus or into a cell comprising an inactivated CCR5 locus) comprises a Trim5alpha or 15 APOBEC3G polypeptide. The sequence may be wild-type or may include one or more mutations, for example mutations that increase anti-viral activity and/or reduce immunogenicity. In certain embodiments, the donor includes a sequence encoding a human Trim5 α protein in which the arginine (R) residue at position 332 is removed or replaced (*e.g.*, with a proline (P) residue or a glutamine (Q) residue, resulting in 20 R332P or R332Q). In other embodiments, the donor includes a sequence encoding a human APOBEC3G D128K mutation.

[0107] The restriction factors (*e.g.*, modified Trim5alpha and/or APOBEC3G) may be integrated alone or in combination with each other or with other anti-HIV therapies described herein (*e.g.*, siRNA, shRNA, engineered transcription 25 factors, etc.).

Dominant-negative HIV rev

[0108] In other aspects, the anti-HIV transgene comprises a dominant negative 30 version of the HIV rev gene, RevM10. The rev gene acts in the transition between early and late gene expression and is required for the transport of unspliced mRNAs from the nucleus into the cytoplasm and for the expression of HIV structural proteins. *See, e.g.*, Kim *et al.* (1989), *J. Virol.* 63(9):3708-13; Malim *et al.* (1989) *Cell* 58(1):205-14. The trans-dominant form of rev, RevM10, has been shown to be effective in inhibiting HIV replication in both cell lines and in primary T-cells. *See,*

e.g., Bevec *et al.* (1992) *Proc. Nat'l. Acad. Sci. USA* 89(20):9870-4; Malim *et al.* (1992) *J. Exp. Med.* 176(4):1197-201. In addition, consistent expression of the trans-dominant protein has not resulted in any adverse effects on normal cell functions or the development of human HSPC's, while still maintaining its inhibitory effect on

5 HIV replication in cells derived from modified human HSPCs. *See*, Bonyhadi *et al.* (1997) *J. Virol.* 71(6):4707-16; Plavec *et al.* (1997) *Gene Therapy* 4(2):128-39.

[0109] Thus, in certain embodiments, donor (transgene) comprises a sequence encoding a RevM10 protein. In certain embodiments, the RevM10-encoding sequence is under the control of a constitutive promoter to ensure consistent high 10 expression of the transgene. The RevM10-encoding sequence can be integrated into the CCR5 locus or into another locus and may be used in combination with other anti-HIV transgenes described (on the same or different vectors and integrated into the same or different sites in any combination).

15 **Suicide cassettes**

[0110] For any of the integrated transgenes described herein, the cell may further comprise a suicide gene cassette that improves safety by allowing for the selective killing of all modified cells (*e.g.*, HSCs) and their resulting progeny by the addition of a small molecule (either *ex-vivo* or *in vivo*). The suicide cassette may be 20 part of, or separate from, one or more donor molecules as described herein.

[0111] Suicide cassettes are known in the art and include the HSV-TK fusion in which the modified cell population can be selectively killed by the addition of ganciclovir that becomes phosphorylated by HSV-TK in cells to interfere with DNA replication in dividing cells. *See, e.g.*, U.S. Patent Publication No. 20110027235.

25

Delivery

[0112] The nucleases, polynucleotides encoding these nucleases, donor polynucleotides (transgenes) and compositions comprising the proteins and/or polynucleotides described herein may be delivered *in vivo* or *ex vivo* by any suitable 30 means.

[0113] Methods of delivering nucleases as described herein are described, for example, in U.S. Patent Nos. 6,453,242; 6,503,717; 6,534,261; 6,599,692; 6,607,882; 6,689,558; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, the disclosures of all of which are incorporated by reference herein in their entireties.

[0114] Nucleases and/or donor constructs as described herein may also be delivered using vectors containing sequences encoding one or more of the zinc finger or TALEN protein(s). Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno-associated virus vectors, etc. *See, also,* U.S. Patent Nos. 6,534,261; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, incorporated by reference herein in their entireties. Furthermore, it will be apparent that any of these vectors may comprise one or more of the sequences needed for treatment. Thus, when one or more nucleases and a donor construct are introduced into the cell, the nucleases and/or donor polynucleotide may be carried on the same vector or on different vectors. When multiple vectors are used, each vector may comprise a sequence encoding one or multiple nucleases and/or donor constructs.

[0115] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding nucleases and donor constructs in cells (*e.g.*, mammalian cells) and target tissues. Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, *Science* 256:808-813 (1992); Nabel & Felgner, *TIBTECH* 11:211-217 (1993); Mitani & Caskey, *TIBTECH* 11:162-166 (1993); Dillon, *TIBTECH* 11:167-175 (1993); Miller, *Nature* 357:455-460 (1992); Van Brunt, *Biotechnology* 6(10):1149-1154 (1988); Vigne, *Restorative Neurology and Neuroscience* 8:35-36 (1995); Kremer & Perricaudet, *British Medical Bulletin* 51(1):31-44 (1995); Haddada *et al.*, in *Current Topics in Microbiology and Immunology* Doerfler and Böhm (eds.) (1995); and Yu *et al.*, *Gene Therapy* 1:13-26 (1994).

[0116] Methods of non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, dendrimers, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, *e.g.*, the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.

[0117] Additional exemplary nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus

Therapeutics Inc, (see for example US6008336). Lipofection is described in e.g., U.S. Patent Nos. 5,049,386; 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include

5 those of Felgner, WO 91/17424, WO 91/16024.

[0118] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, *Science* 270:404-410 (1995); Blaese *et al.*, *Cancer Gene Ther.* 2:291-297 (1995); Behr *et al.*, *Bioconjugate Chem.* 5:382-389 (1994); Remy *et al.*, 10 *Bioconjugate Chem.* 5:647-654 (1994); Gao *et al.*, *Gene Therapy* 2:710-722 (1995); Ahmad *et al.*, *Cancer Res.* 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

[0119] Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGeneIC delivery vehicles (EDVs). These EDVs 15 are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see MacDiarmid *et al* (2009) *Nature Biotechnology* 27(7):643).

20 [0120] The use of RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered ZFPs take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (*in vivo*) or they can be used to treat cells *in vitro* and the modified cells are administered to patients 25 (*ex vivo*). Conventional viral based systems for the delivery of ZFPs include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated, vaccinia and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high 30 transduction efficiencies have been observed in many different cell types and target tissues.

[0121] The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral

vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system depends on the target tissue. Retroviral vectors are comprised of *cis*-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The 5 minimum *cis*-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and 10 combinations thereof (see, e.g., Buchscher *et al.*, *J. Virol.* 66:2731-2739 (1992); Johann *et al.*, *J. Virol.* 66:1635-1640 (1992); Sommerfelt *et al.*, *Virol.* 176:58-59 (1990); Wilson *et al.*, *J. Virol.* 63:2374-2378 (1989); Miller *et al.*, *J. Virol.* 65:2220-2224 (1991); PCT/US94/05700).

15 [0122] In applications in which transient expression is preferred, adenoviral based systems can be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Adeno-associated virus (“AAV”) vectors are also used to transduce cells with target nucleic acids, *e.g.*, in the 20 *in vitro* production of nucleic acids and peptides, and for *in vivo* and *ex vivo* gene therapy procedures (see, *e.g.*, West *et al.*, *Virology* 160:38-47 (1987); U.S. Patent No. 4,797,368; WO 93/24641; Kotin, *Human Gene Therapy* 5:793-801 (1994); Muzychka, *J. Clin. Invest.* 94:1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; 25 Tratschin *et al.*, *Mol. Cell. Biol.* 5:3251-3260 (1985); Tratschin, *et al.*, *Mol. Cell. Biol.* 4:2072-2081 (1984); Hermonat & Muzychka, *PNAS* 81:6466-6470 (1984); and Samulski *et al.*, *J. Virol.* 63:03822-3828 (1989).

30 [0123] At least six viral vector approaches are currently available for gene transfer in clinical trials, which utilize approaches that involve complementation of defective vectors by genes inserted into helper cell lines to generate the transducing agent.

[0124] pLASN and MFG-S are examples of retroviral vectors that have been used in clinical trials (Dunbar *et al.*, *Blood* 85:3048-305 (1995); Kohn *et al.*, *Nat. Med.* 1:1017-102 (1995); Malech *et al.*, *PNAS* 94:22 12133-12138 (1997)).

PA317/pLASN was the first therapeutic vector used in a gene therapy trial. (Blaese *et al.*, *Science* 270:475-480 (1995)). Transduction efficiencies of 50% or greater have been observed for MFG-S packaged vectors. (Ellem *et al.*, *Immunol Immunother.* 44(1):10-20 (1997); Dranoff *et al.*, *Hum. Gene Ther.* 1:111-2 (1997)).

5 [0125] Recombinant adeno-associated virus vectors (rAAV) are a promising alternative gene delivery systems based on the defective and nonpathogenic parvovirus adeno-associated type 2 virus. All vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to 10 integration into the genomes of the transduced cell are key features for this vector system. (Wagner *et al.*, *Lancet* 351:9117 1702-3 (1998), Kearns *et al.*, *Gene Ther.* 9:748-55 (1996)). Other AAV serotypes, including AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 and AAVrh10 can also be used in accordance with the present invention.

15 [0126] Replication-deficient recombinant adenoviral vectors (Ad) can be produced at high titer and readily infect a number of different cell types. Most adenovirus vectors are engineered such that a transgene replaces the Ad E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in *trans*. Ad vectors can transduce 20 multiple types of tissues *in vivo*, including non-dividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity. An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for anti-tumor immunization with intramuscular injection (Sterman *et al.*, *Hum. Gene Ther.* 7:1083-9 (1998)). Additional examples of the use 25 of adenovirus vectors for gene transfer in clinical trials include Rosenecker *et al.*, *Infection* 24:1 5-10 (1996); Sterman *et al.*, *Hum. Gene Ther.* 9:7 1083-1089 (1998); Welsh *et al.*, *Hum. Gene Ther.* 2:205-18 (1995); Alvarez *et al.*, *Hum. Gene Ther.* 5:597-613 (1997); Topf *et al.*, *Gene Ther.* 5:507-513 (1998); Sterman *et al.*, *Hum. Gene Ther.* 7:1083-1089 (1998).

30 [0127] Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ψ2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for

packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The missing viral functions are supplied in *trans* by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess inverted terminal repeat

5 (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely *rep* and *cap*, but lacking ITR sequences. The cell line is also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes
10 from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, *e.g.*, heat treatment to which adenovirus is more sensitive than AAV. In some cases, the AAV may be produced in baculovirus (see U.S. Patent Nos. 6,723,551 and 7,271,002, incorporated herein by reference).

15 [0128] In many gene therapy applications, it is desirable that the gene therapy vector be delivered with a high degree of specificity to a particular tissue type. Accordingly, a viral vector can be modified to have specificity for a given cell type by expressing a ligand as a fusion protein with a viral coat protein on the outer surface of the virus. The ligand is chosen to have affinity for a receptor known to be present on
20 the cell type of interest. For example, Han *et al.*, *Proc. Natl. Acad. Sci. USA* 92:9747-9751 (1995), reported that Moloney murine leukemia virus can be modified to express human heregulin fused to gp70, and the recombinant virus infects certain human breast cancer cells expressing human epidermal growth factor receptor. This principle can be extended to other virus-target cell pairs, in which the target cell expresses a
25 receptor and the virus expresses a fusion protein comprising a ligand for the cell-surface receptor. For example, filamentous phage can be engineered to display antibody fragments (*e.g.*, FAB or Fv) having specific binding affinity for virtually any chosen cellular receptor. Although the above description applies primarily to viral vectors, the same principles can be applied to nonviral vectors. Such vectors can be
30 engineered to contain specific uptake sequences which favor uptake by specific target cells.

[0129] Gene therapy vectors can be delivered *in vivo* by administration to an individual patient, typically by systemic administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical

application, as described below. Alternatively, vectors can be delivered to cells *ex vivo*, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem/progenitor cells, followed by reimplantation of the cells into a patient, usually after selection for 5 cells which have incorporated the vector.

[0130] Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containing nucleases and/or donor constructs can also be administered directly to an organism for transduction of cells *in vivo*. Alternatively, naked DNA formulated/complexed with a delivery vehicle (e.g. liposome or poloxamer) can be administered. Administration is 10 by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often 15 provide a more immediate and more effective reaction than another route.

[0131] Vectors suitable for introduction of polynucleotides described herein include non-integrating lentivirus vectors or integrase-defective lentivirus (IDLV). See, for example, Ory *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:11382-11388; Dull *et al.* (1998) *J. Virol.* **72**:8463-8471; Zuffery *et al.* (1998) *J. Virol.* **72**:9873-9880; 20 Follenzi *et al.* (2000) *Nature Genetics* **25**:217-222; U.S. Patent Publication No 2009/054985.

[0132] Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable 25 formulations of pharmaceutical compositions available, as described below (see, e.g., *Remington's Pharmaceutical Sciences*, 17th ed., 1989).

[0133] It will be apparent that the nuclease-encoding sequences and donor constructs can be delivered using the same or different systems. For example, a donor polynucleotide can be carried by a plasmid, while the one or more nucleases can be 30 carried by a AAV vector. Furthermore, the different vectors can be administered by the same or different routes (intramuscular injection, tail vein injection, other intravenous injection, intraperitoneal administration and/or intramuscular injection. The vectors can be delivered simultaneously or in any sequential order.

[0134] Formulations for both *ex vivo* and *in vivo* administrations include suspensions in liquid or emulsified liquids. The active ingredients often are mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients include, for example, water, saline, dextrose, glycerol, 5 ethanol or the like, and combinations thereof. In addition, the composition may contain minor amounts of auxiliary substances, such as, wetting or emulsifying agents, pH buffering agents, stabilizing agents or other reagents that enhance the effectiveness of the pharmaceutical composition.

10 [0135] The following Examples relate to exemplary embodiments of the present disclosure in which the nuclease comprises a zinc finger nuclease (ZFN). It will be appreciated that this is for purposes of exemplification only and that other nucleases can be used, for instance homing endonucleases (meganucleases) with engineered DNA-binding domains and/or fusions of naturally occurring or engineered 15 homing endonucleases (meganucleases) DNA-binding domains and heterologous cleavage domains or TALENs.

EXAMPLES

Example 1: Integration of anti-HIV transgenes into the CCR5 locus

20 [0136] Zinc finger nucleases as described in U.S. Patent No. 7,951,925 are used for targeted integration of anti-HIV transgenes encoded on donor molecules into the CCR5 gene locus in K562 cells, PM-1 cells or human HSPCs (e.g., CD34+ cells). For shRNA donors, a U6, CAG or PGK promoter drives expression of the shRNA. For ZFP-TF repressor donors, the donors include a CD4 promoter/enhancer to restrict 25 downregulation in CD4+ T-cells. These expression cassettes would be cloned into the lead CCR5 donor for human and rhesus HSCs (identified above) and sequence confirmed.

[0137] The ZFNs and/or donor constructs are delivered using plasmids and/or viral vectors (e.g., adenovirus). The targeted integration rate is measured in K562 30 cells to ensure the expected activity and validate donor integration. After validation in K562 cells, PM-1 cells are transfected in a similar manner to modify the endogenous CCR5 locus, and the frequency of modification measured. Transfected populations and clones would be isolated to look at overall frequency, level and

stability of transgene expression when integrated into the CCR5 locus, and for off-target effects.

[0138] The modified PM-1 population and cell clones exhibiting good, stable expression of the transgene are challenged with a variety of HIV strains, including 5 R5-tropic, X4-tropic, and dual tropic virus, to determine which combination of CCR5 disruption and transgene gives the best and broadest resistance to HIV. Resistance is monitored by measuring the survival of modified cells by PCR, overall cell survival, extracellular p24 levels, the units of Reverse Transcriptase (RT) present in the culture, or by measuring the amounts of viral message in the growth media by qRT-PCR.

10 [0139] Selected donor/transgene combinations are then used to develop high titer NIL vectors, which may include altering the configuration of the vector to have all three components, have them broken into two separate vectors, or have the components placed in the sense or antisense orientations. The resulting NIL vectors are used to modify HSPCs and test the expression and stability of these transgenes to 15 function in a wide variety of cell types both *ex vivo* and in *in vivo* animal studies, including testing for genotoxicity and off-target effects.

Example 2: Suicide Cassettes

[0140] An HSV TK gene expression cassette driven by the EF1 α promoter is cloned and sequenced and inserted into the optimal CCR5 donor molecule (Example 20 1) and the resulting construct tested in K562 and PM-1 cells to determine the frequency of integration and the level and stability of HSV TK expression in transfected cells. Studies are performed to look at the stability and level of expression over time. Kill curves are generated to examine the response of the modified population and of isolated cell clones to ganciclovir and the efficiency of killing.

25

[0141] All patents, patent applications and publications mentioned herein are hereby incorporated by reference in their entirety.

[0142] Although disclosure has been provided in some detail by way of 30 illustration and example for the purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications can be practiced without departing from the spirit or scope of the disclosure. Accordingly, the foregoing descriptions and examples should not be construed as limiting.

CLAIMS

What is claimed is:

1. A method of inhibiting HIV infection or replication in a cell, the method
5 comprising:
introducing an anti-HIV transgene into a target site in the genome of the cell, wherein
the anti-HIV transgene is integrated into the genome following double-stranded
cleavage of the target site by a non-naturally occurring zinc finger nuclease (ZFN),
and further wherein the anti-HIV transgene is expressed in the cell, thereby inhibiting
10 HIV infection or replication.
2. The method of claim 1, wherein the anti-HIV transgene is selected from the
group consisting of a sequence encoding a zinc finger transcription factor that
represses an HIV polyprotein, a sequence encoding a zinc finger transcription factor
15 that represses expression of an HIV receptor, a CCR5 ribozyme, an siRNA sequence
targeted to an HIV polyprotein, a sequence encoding a Trim5alpha (Trim5 α)
restriction factor, a sequence encoding an APOBEC3G restriction factor, a sequence
encoding a RevM10 protein, a suicide cassette and combinations thereof.
- 20 3. The method of claim 1 or 2, wherein the target site is in an endogenous
gene selected from the group consisting of CCR5, CCR4, AAVS1, HPRT, albumin
and *Rosa*.
- 25 4. The method of claim 3, wherein the target site is in an endogenous CCR5
gene.
5. The method of claim 3, wherein the endogenous gene is inactivated.

6. The method of any of claims 1 to 5, wherein the cell is selected from the group consisting of a stem cell, a T-cell, a macrophage, a dendritic cell or an antigen-presenting cell.

7. The method of claim 6, wherein the stem cell is selected from the group
5 consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC) and a hematopoietic stem/progenitor cells (HSPCs).

8. The method of any of claims 1 to 7, wherein the endogenous CCR5 gene in the cell is inactivated.

10

9. The method of any of claims 1 to 8, wherein the endogenous CXCR4 gene in the cell is inactivated.

10. The method of any of claims 1 to 9, wherein expression of the integrated
15 anti-HIV transgene is driven by an endogenous promoter.

11. The method of any of claims 1 to 9, wherein the anti-HIV transgene comprises a promoter that drives expression of the transgene.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/58775

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - C12N 15/55; A61K 31/7088 (2012.01)
 USPC - 435/462; 514/44R

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 USPC - 435/462; 514/44R

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 USPC - 435/440, 455 (text search, see terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PatBase; PubWEST (PGPB, USPT, EPAB, JPAB); Google Scholar (text search, see terms below)

Search Terms: ZFN, zinc finger nuclease, zinc finger endonuclease, homing endonuclease, CCR5\$, target site, transgene, exogenous, anti-HIV, revM10, APOBEC3G, trim5a, trim5alpha, siRNA, shRNA, zinc finger transcription factor, anti-HIV transgene

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2009/0258363 A1 (GREGORY et al.) 15 October 2009 (15.10.2009) para [0305]; [0313]; [0327]	1-5
X	US 2008/0003681 A1 (BANGEREA et al.) 3 January 2008 (03.01.2008) para [0015]; [0028]	1-5
A	US 2011/0136895 A1 (GREGORY et al.) 9 June 2011 (09.06.2011)	1-5
A	US 2011/059160 A1 (ESSNER et al.) 10 March 2011 (10.03.2011)	1-5
A	Li et al. "Long term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy"; Molecular Therapy; 2005, Vol. 12, No. 5; pp 900-909; Abstract; Figure 3 and legend; (page 901, col 1, para 1), (page 902, col 2, para 1), (page 903, col 2, para 1, 2), (page 908, col 1, para 4)	1-5
A	US 2010/0055793 A1 (CHANDRASEGARAN) 4 March 2010 (04.03.2010); paras [0006], [0044]	1-5

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search	Date of mailing of the international search report
22 December 2012 (22.12.2012)	01 FEB 2013
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/58775

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 6-11
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

<input type="checkbox"/>	The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
<input type="checkbox"/>	The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
<input type="checkbox"/>	No protest accompanied the payment of additional search fees.